Imaging Biomarkers of Progression of Mobility Impairment in Parkinson Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01106976|
Recruitment Status : Completed
First Posted : April 20, 2010
Results First Posted : February 1, 2016
Last Update Posted : February 1, 2016
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||67 participants|
|Official Title:||Imaging Biomarkers of Progression of Mobility Impairment in Parkinson Disease|
|Study Start Date :||May 2010|
|Actual Primary Completion Date :||September 2014|
|Actual Study Completion Date :||March 2015|
Group 1 Parkinson disease subjects
Subjects with Parkinson disease who previously participate in a motor and brain PET (brain positron emission tomography) imaging study who were invited for a longitudinal observational study.
- AChE PET Neuroimaging [ Time Frame: 4 yr ]AChE PMP PET hydrolysis rate outcome measure. AChE [11C]PMP hydrolysis rates (k3) were estimated using the striatal volume of interest (defined by manual tracing on the MRI scan of the putamen and caudate nucleus) as the tissue reference for the integral of the precursor delivery. This measure is a proxy measure for the count of cholinergic nerve terminals in the basal forebrain innervation the cortical mantle.
Biospecimen Retention: None Retained
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01106976
|United States, Michigan|
|VA Ann Arbor Healthcare System, Ann Arbor, MI|
|Ann Arbor, Michigan, United States, 48105|
|Principal Investigator:||Nicolaas I Bohnen, MD PhD||VA Ann Arbor Healthcare System, Ann Arbor, MI|